✨ Free AI Report
IO Biotech, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research IO Biotech, Inc.
Company Research

IO Biotech, Inc.: Business Overview, Financials & Competitive Analysis

IO Biotech, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). High-risk early-stage biotech with promising immune-oncology technology but facing clinical execution challenges and severe capital constraints requiring strategic pivot or partnership. IO Biotech demonstrates strong scientific credentials and innovative technology platform, evidenced by Phase 3 data and Fast Company recognition. However, significant clinical trial setback (Phase 3 missed primary.

What is IO Biotech, Inc.'s industry? IO Biotech, Inc. (iobiotech.com) operates in Biopharmaceutical/Immuno-Oncology. AskCyborg classifies IO Biotech, Inc. under Biopharmaceutical/Immuno-Oncology in its company registry.

IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead candidate, Cylembio (IO102-IO103), demonstra...

4/ 10Mixed

Cyborg Score thesis

High-risk early-stage biotech with promising immune-oncology technology but facing clinical execution challenges and severe...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Immuno-Oncology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest IO Biotech, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for IO Biotech, Inc.

AskCyborg analysts argue the bull and bear cases for IO Biotech, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
IO Biotech, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

IO Biotech, Inc. Overview

Pro stress-test →

IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead candidate, Cylembio (IO102-IO103), demonstrated clinical improvement in progression-free survival in a Phase 3 trial for advanced melanoma, though it narrowly missed statistical significance versus pembrolizumab monotherapy.

Strategic Profile

Pro stress-test →

The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. The company has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025, positioning it as a leader in next-generation cancer immunotherapy with a differentiated dual-targeting mechanism.

Competitive Landscape

Pro stress-test →

IO Biotech's lead candidate targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). The company competes in the crowded immuno-oncology space with established players like Merck (Keytruda), Bristol Myers Squibb, and Roche, as well as emerging cancer vaccine developers such as BioNTech and CureVac. IO Biotech's differentiation lies in its dual-targeting T-win platform, though commercial viability remains unproven following the Phase 3 setback.

Industry Context

IO Biotech, Inc. operates in Biopharmaceutical/Immuno-Oncology.

Key facts

Founded: 2014 · Headquarters: Copenhagen, Denmark · Employees: 78-80 · Revenue: $35M (as of May 2025) · Market cap: $23.21M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on IO Biotech, Inc..

  • Phase 3 trial narrowly missed statistical significance on primary endpoint despite showing clinical improvement, creating regulatory uncertainty for lead program Cylembio
  • Stock down 88% from 52-week highs; recent restructuring and Raymond James engagement signals financial distress and potential strategic alternatives
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Raymond James engaged as financial advisor; workforce reduction implemented
  • November 2025Phase 3 melanoma trial topline data presented at ESMO showing clinical improvement in PFS across subgroups
  • +2 moreTrack every material event for IO Biotech, Inc. as it happens. Explore monitoring →
Get alerted when IO Biotech, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Keytruda (pembrolizumab)Anti-PD-1 immunotherapy; the standard-of-care comparator in IO Biotech's Phase 3 melanoma trial→BioNTech cancer vaccinesPersonalized neoantigen cancer vaccines in late-stage development→Imfinzi (durvalumab)Anti-PD-L1 immunotherapy for multiple cancer types→

Compare IO Biotech, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

IO Biotech, Inc. operates in Biopharmaceutical/Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about IO Biotech, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare IO Biotech, Inc. and its top competitor on Cyborg Score”
“What did IO Biotech, Inc. do this quarter?”
“Is IO Biotech, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does IO Biotech, Inc. do?+
IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead candidate, Cylembio (IO102-IO103), demonstra...
What is IO Biotech, Inc.'s Cyborg Score?+
IO Biotech, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are IO Biotech, Inc.'s main competitors?+
Named competitors include Keytruda (pembrolizumab), BioNTech cancer vaccines, Imfinzi (durvalumab). The full competitive landscape is in the AskCyborg report.
How can I get the full IO Biotech, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the IO Biotech, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track IO Biotech, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score